• SPX
  • $5,699.94
  • -0.17 %
  • -$9.60
  • DJI
  • $42,011.59
  • -0.44 %
  • -$184.93
  • N225
  • $38,635.62
  • 0.22 %
  • $83.56
  • FTSE
  • $8,245.17
  • -0.45 %
  • -$37.35
  • IXIC
  • $17,918.48
  • -0.04 %
  • -$6.65
SQZ Biotechnologies Company (SQZ) Stock Price, News & Analysis

SQZ Biotechnologies Company (SQZ) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$0.38
Day's range
$0.57
50-day range
$0.046
Day's range
$0.5678
  • Country: US
  • ISIN: US78472W1045
52 wk range
$0.25
Day's range
$3.56
  • CEO: Dr. Howard Bernstein M.D., Ph.D.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -22.95
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (SQZ)
  • Company SQZ Biotechnologies Company
  • Price $0.44
  • Changes Percentage (61.11%)
  • Change $0.17
  • Day Low $0.38
  • Day High $0.57
  • Year High $3.56

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 08/02/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $400.00
  • High Stock Price Target $400.00
  • Low Stock Price Target $400.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.16
  • Trailing P/E Ratio -0.20138888888889
  • Forward P/E Ratio -0.20138888888889
  • P/E Growth -0.20138888888889
  • Net Income $-78,244,000

Income Statement

Quarterly

Annual

Latest News of SQZ

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.